HM242-Solution vs Comparator

Inclusion Criteria: * Males or females of at least 18 years at the time of enrolment * Has the legal capacity and is able to understand the nature, risks, significance and scope of the clinical trial and to determine his or her will accordingly * Signed form of consent, including the understanding of and willingness by the patient to participate in the clinical study and ability to comply with study procedures and study visit schedule * Patients must be willing to have all dressing changes performed by the wound specialist, with no treatments at home * Presence of at least one venous ulcer of the lower leg extending through the full thickness of the skin but not down to muscle, tendon or bone * Size of study ulcer ≥ 2cm² and ≤ 100cm² measured using the tracing method * Presence of venous leg ulcer for at least 6 weeks, but not longer than 12 months * Ankle Brachial Pressure Index (ABI) \> 0.75 * In the case of a female patient of childbearing potential, willingness to use highly effective methods of contraception (failure rate of \< 1% when used consistently and correctly); acceptable contraceptive measures in this trial are: combined pill and progestin-only pill, contraceptive patch, ring or injection, Etonogestrel implant, intrauterine device (IUD) (copper and Levonogestrel), male sterilization (vasectomy), female sterilization (abdominal, laparoscopic, hysteroscopic), or sexual abstinence. Exclusion Criteria: * Patients kept in an institution due to an official or court order * Patients dependent on the Sponsor, Investigator or Site * Patients suspected of having SARS-CoV-2 infection or COVID-19 disease * Study ulcer judged by the Investigator to be caused by a medical condition other than venous insufficiency * Study ulcer with signs and symptoms of infection, or under suspicion of cancer * Study ulcer under treatment with topical antimicrobials within past two weeks or systemic antimicrobial treatment within past two weeks * More than two venous leg ulcers or more than two chronic wounds * Dementia stage greater than 3 according to Reisberg * Known allergies against wound dressings used in the study * Known chronical skin diseases, dermatoses, or known allergies or other conditions which might trigger dermatitis * Acute cases of substance use disorders (ICD-10 F1x.1 or F1x.2) * Buerger's disease * Participation in Medical Device trials less than 4 weeks ago or participation in Drug trials less than six months ago * Terminally ill patients * Patients with poorly managed diabetes mellitus: absence of a glycated hemoglobin test within the last 3 months or a result of HbA1c ≥ 8% not older than 3 months, or a major diabetes-related incident within the past 4 weeks * Ulcers of diabetic origin * Patients under treatment with systemic corticosteroids, immunosuppressants, cytotoxic chemotherapy, or radiotherapy * Presence of one or more medical conditions (other than venous insufficiency and diabetes) as determined by medical history, which: * Is known to interfere with the wound healing process (e.g. arteriopathy, vasculitis, rheumatoid arthritis, systemic lupus erythematosus, other auto-immune diseases, cancer, immunodeficiency, severe lymphedema of the leg, thrombophilia) * In the opinion of the Investigator, would make the patient an inappropriate candidate for this venous ulcer healing study (e.g. malnutrition, hygiene, obesity) * Pregnant or lactating patients